The company’s ongoing clinical trials feature two leading candidates: PLN-74809, also known as bexotegrast, and PLN-1474. These programs are currently at the clinical trial stage the company has two additional research tracks, targeting solid tumors and various muscular dystrophies, undergoing preclinical studies. Pliant’s research pipeline, for the moment, is targeting diseases of those two organs, including idiopathic pulmonary fibrosis (IPF), primary sclerosing cholangitis (PSC), and NASH-associated liver fibrosis. These diseases can affect various organ systems in the body, including the lungs and liver. Fibrotic diseases belong to a class where abnormal deposition of connective tissue, typically occurring during wound healing and scarring, obstructs and inhibits normal organ function. We’ll start with Pliant Therapeutics, a clinical-stage biopharmaceutical firm that focuses on the discovery and development of novel treatments for fibrotic diseases. Using the TipRanks platform, we’ve pinpointed two equities in the small-cap category, both offering ‘Strong Buy’ ratings and both with more than 100% upside potential, according to the analyst forecasts. We can put Belski’s point into action and start following some of the smaller stocks with high upside. That being said, however, our work shows that once relative performance of these megacaps has subsided or winning streaks have ended, the broader market has historically held up just fine with gains being more common than losses.” As BMO’s chief investment strategist Brian Belski points out, there are other games in town: “There is no denying the sharp outperformance of mega-caps in 2023 with the five largest stocks by market cap eclipsing the S&P 500 by 30 percentage points YTD and on pace to outperform for the fifth straight month. But that doesn’t mean investors have to stay locked into the few dominant mega-cap stocks. This kind of scale makes the market giants hard to ignore. ![]() That $6.9 trillion is a higher market cap than every national stock market in the world outside of the US. To give an idea of the scale, the three largest S&P-listed companies are Apple, Microsoft, and Alphabet together, they have a combined market cap over $6.9 trillion and make up a big chunk of the S&P 500’s total value. The mega-caps, the largest US companies, have been outperforming the broader indexes, and by their very size they are pulling the rest of the markets along. ![]() If there’s one way to describe the markets recently, that would be top-heavy.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |